-
Product Insights
NewNet Present Value Model: Otonomy Inc’s OTO-413
Empower your strategies with our Net Present Value Model: Otonomy Inc's OTO-413 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Acute Sensorineural Hearing Loss – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Drugs In Development, 2023’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hearing Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Hearing Disorders - Drugs In Development, 2023’, provides an overview of the Hearing Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Company Profile
Otonomy Inc – Company Profile
Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients and otitis externa. Its pipeline portfolio encompasses Otividex for the treatment of meniere’s disease; OTO-313 for the treatment of tinnitus; OTO-510 for the treatment of cisplatin-induced hearing loss; OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. The company...
Add to Basket -
Product Insights
Net Present Value Model: OTO-413
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model OTO-413 Drug Details OTO-413 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OTO-413
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OTO-413 Drug Details OTO-413 is under development for the repair of cochlear synaptopathy and...
-
Product Insights
Tinnitus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Tinnitus pipeline market report provides a comprehensive overview of the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued...
-
Product Insights
Tinnitus – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Tinnitus - Global Clinical Trials Review, H2, 2021" provides an overview of Tinnitus Clinical trials scenario. This report provides top line data relating to the clinical trials on Tinnitus . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
Hearing Disorders Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Hearing Disorders Global Clinical Trials Review, H2, 2020" provides an overview of Hearing Disorders Clinical trials scenario. This report provides top line data relating to the clinical trials on Hearing Disorders. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Otitis Externa Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Otitis Externa Global Clinical Trials Review, H1, 2018" provides an overview of Otitis Externa clinical trials scenario. This report provides top line data relating to the clinical trials on Otitis Externa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...